Neural Network Models for Predicting Solubility and Metabolism Class of Drugs in the Biopharmaceutics Drug Disposition Classification System (BDDCS)

被引:0
|
作者
Ashrafi, Aryan [1 ]
Teimouri, Kiarash [2 ]
Aghazadeh, Farnaz [3 ]
Shayanfar, Ali [4 ,5 ]
机构
[1] Univ Tabriz, Fac Elect & Comp Engn, Tabriz, Iran
[2] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran
[3] Tabriz Univ Med Sci, Biotechnol Res Ctr, Tabriz, Iran
[4] Tabriz Univ Med Sci, Pharmaceut Anal Res Ctr, Tabriz, Iran
[5] Tabriz Univ Med Sci, Fac Pharm, Golgasht St, Tabriz 5166614766, East Azerbaijan, Iran
关键词
BCS; PARAMETERS; LOGD;
D O I
10.1007/s13318-023-00861-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and ObjectiveThe biopharmaceutics drug disposition classification system (BDDCS) categorizes drugs into four classes on the basis of their solubility and metabolism. This framework allows for the study of the pharmacokinetics of transporters and enzymatic metabolization on biopharmaceuticals, as well as drug-drug interactions in the body. The objective of the present study was to develop computational models by neural network models and structural parameters and physicochemical properties to estimate the class of a drug in the BDDCS system.MethodsIn this study, deep learning methods were utilized to explore the potential of artificial and convolutional neural networks (ANNs and CNNs) in predicting the BDDCS class of 721 substances. The structural parameters and physicochemical properties [Abraham solvation parameters, octanol-water partition (log P) and over the pH range 1-7.5 (log D), number of rotatable bonds, hydrogen bond acceptor numbers, as well as hydrogen bond donor count] are calculated with various software. These compounds were then split into a training set consisting of 602 molecules and a test set of 119 compounds to validate the models.ResultsThe results of this study showed that neural network models using applied parameters of the drug, i.e., log D and Abraham solvation parameters, are able to predict the class of solubility and metabolism in the BDDCS system with good accuracy.ConclusionsNeural network models are well equipped to deal with the relations between the structural parameters and physicochemical properties of drugs and BDDCS classes. In addition, log D is a more suitable parameter compared with log P in predicting BDDCS.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 50 条
  • [21] A Comparative Analysis of Biopharmaceutics Classification System and Biopharmaceutics Drug Disposition Classification System: A Cross-Sectional Survey with 500 Bioequivalence Studies
    Cristofoletti, Rodrigo
    Chiann, Chang
    Dressman, Jennifer B.
    Storpirtis, Silvia
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 102 (09) : 3136 - 3144
  • [22] Statistical investigation of simulated intestinal fluid composition on the equilibrium solubility of biopharmaceutics classification system class II drugs
    Khadra, Ibrahim
    Zhou, Zhou
    Dunn, Claire
    Wilson, Clive G.
    Halbert, Gavin
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 67 : 65 - 75
  • [23] DRUG SOLUBILITY IN THE CONTEXT OF AN INHALATION-BASED BIOPHARMACEUTICS CLASSIFICATION SYSTEM (IBCS)
    Floroiu, Andreea
    Loretz, Brigitta
    Kraemer, Johannes
    Lehr, Claus-Michael
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2023, 36 (06) : A10 - A10
  • [24] Intrinsic Dissolution as a Tool for Evaluating Drug Solubility in Accordance with the Biopharmaceutics Classification System
    Issa, Michele G.
    Ferraz, Humberto G.
    DISSOLUTION TECHNOLOGIES, 2011, 18 (03): : 6 - 13
  • [25] Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs Cimetidine and Acyclovir
    Vaithianathan, Soundarya
    Haidar, Sam H.
    Zhang, Xinyuan
    Jiang, Wenlei
    Avon, Christopher
    Dowling, Thomas C.
    Shao, Changxing
    Kane, Maureen
    Hoag, Stephen W.
    Flasar, Mark H.
    Ting, Tricia Y.
    Polli, James E.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 105 (02) : 996 - 1005
  • [26] Feasibility of Biowaiver Extension to Biopharmaceutics Classification System Class III Drug ProductsCimetidine
    Ekarat Jantratid
    Sompol Prakongpan
    Gordon L. Amidon
    Jennifer B. Dressman
    Clinical Pharmacokinetics, 2006, 45 : 385 - 399
  • [27] The biopharmaceutics classification system (BCS): Class III drugs - better candidates for BA/BE waiver?
    Blume, HH
    Schug, BS
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 9 (02) : 117 - 121
  • [28] Optimizing Solubility and Permeability of a Biopharmaceutics Classification System (BCS) Class 4 Antibiotic Drug Using Lipophilic Fragments Disturbing the Crystal Lattice
    Tehler, Ulrika
    Fagerberg, Jonas H.
    Svensson, Richard
    Larhed, Mats
    Artursson, Per
    Bergstrom, Christel A. S.
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (06) : 2690 - 2694
  • [29] Possibility of extending biopharmaceutics classification system based biowaiver to BCS class Ha drug
    Khalid, Farah
    Hassan, Syed Muhammad Farid
    Noor, Rabia
    Zaheer, Kamran
    Hassan, Fouzia
    Muhammad, Iyad Naeem
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 32 (05) : 2065 - 2073
  • [30] Drug solubility in biorelevant media in the context of an inhalation-based biopharmaceutics classification system (iBCS)
    Floroiu, Andreea
    Loretz, Brigitta
    Kraemer, Johannes
    Lehr, Claus-Michael
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2024, 197